Frequency of the Phenotypes of Polycystic Ovarian Syndrome in Iranian Adolescents (Mashhad) based on Rotterdam Criteria in 2018

Document Type : Original Article

Authors

1 Assistant Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Mashhad University of Medical of Sciences, Mashhad, Iran.

2 Assistant Professor, Department of Midwifery, Nursing and Midwifery Care Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Instructor, Department of Midwifery, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Instructor, Department of Nursing, Nursing and Midwifery Care Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Introduction: Polycystic ovary syndrome (PCOs) is the most common endocrine disorder in women. Due to the fact that PCOS starts from adolescence, this study was conducted with aim to investigate the prevalence of this syndrome and its phenotypes based on Rotterdam criteria in adolescent girls in Mashhad.
Methods: This cross-sectional study was performed on 650 girls aged 14 to 19 years in public schools of Mashhad in 2018-2019. Sampling was performed as a multi-stage classified cluster. After completing the Individual and Demographic Information Questionnaire, if they had criteria for entering the study, a clinical examination was performed to investigate the clinical symptoms of hyperandrogenism, including hirsutism, acne, and hair loss with the male pattern, and if any of the above symptoms were positive, they were referred for hormonal tests and sonography. The diagnosis of polycystic ovary syndrome and its phenotypes was made based on Rotterdam criteria. Data were analyzed by SPSS software (version 22) and Chi-square and Fisher tests. P<0.05 was considered statistically significant.
Results: Frequency of quadruple phenotypes of polycystic ovary syndrome based on Rotterdam criteria included phenotype A(clinical hyperandrogenism / biochemistry + polycystic ovary) was found in 3 people (7.7%), phenotype B (menstrual disorders + clinical hyperandrogenism / biochemistry) in 11 (28.2%), phenotype C (menstrual disorders + polycystic ovaries) in 14 (35.9%) and phenotype D (menstrual disorders + clinical hyperandrogenism / biochemistry + polycystic ovaries) in 11(28.2%). The overall prevalence of PCOs was 6.8% based on Rotterdam criteria.
Conclusion: Due to the prevalence of four phenotypes of polycystic ovary syndrome and the similarity of symptoms with clinical manifestations of adolescence, it is better to start the diagnosis and treatment of this syndrome from adolescence.

Keywords

References

  1. Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. Hum Reprod Update 2010; 16(1):51-64.
  2. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91(11):4237-45.
  3. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 2011; 9:39.
  4. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25(2):544-51.
  5. Mehrabian F, Khani B, Kelishadi R, Ghanbari E. The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynol Pol 2011; 62(3):238-42.
  6. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12(6):673-83.
  7. Kashanian M, Fazy Z, Pirak A. Evaluation of the relationship between gestational diabetes and a history of polycystic ovarian syndrome. Diabetes Res Clin Pract 2008; 80(2):289-92.
  8. Głuszak O, Stopińska-Głuszak U, Glinicki P, Kapuścińska R, Snochowska H, Zgliczyński W, et al. Phenotype and metabolic disorders in polycystic ovary syndrome. ISRN Endocrinol. 2012;2012:569862.
  9. Stankiewicz M, Norman R. Diagnosis and management of polycystic ovary syndrome: a practical guide. Drugs 2006; 66(7):903-12.
  10. Pastore LM, Patrie JT, Morris WL, Dalal P, Bray MJ. Depression symptoms and body dissatisfaction association among polycystic ovary syndrome women. J Psychosom Res 2011; 71(4):270-6.
  11. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007; 370(9588):685-97.
  12. Broder-Fingert S, Shah B, Kessler M, Pawelczak M, David R. Evaluation of adolescents for polycystic ovary syndrome in an urban population. J Clin Res Pediatr Endocrinol 2009; 1(4):188-93.
  13. Moran C, Arriaga M, Rodriguez G, Moran S. Obesity differentially affects phenotypes of polycystic ovary syndrome. Int J Endocrinol. 2012;2012:317241.
  14. Chhabra S, McCartney CR, Yoo RY, Eagleson CA, Chang RJ, Marshall JC. Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls. J Clin Endocrinol Metab 2005; 90(5):2810-5.
  15. Zawadzski JK. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic ovary syndrome 1992: 39-50.
  16. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91(2):456-88.
  17. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81(1):19-25.
  18. Kaewnin J, Vallibhakara O, Arj-Ong Vallibhakara S, Wattanakrai P, Butsripoom B, Somsook E, et al. Prevalence of polycystic ovary syndrome in Thai University adolescents. Gynecol Endocrinol 2018; 34(6):476-480.
  19. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005; 34(3):677-705.
  20. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91(2):492-7.
  21. Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. Hum Reprod Update 2010; 16(1):51-64.
  22. Poli F, Taieb C, Ambonati M, Boussetta S. Acne and quality of life: the pertinence of the CADI score. InJournal of the American Academy of Dermatology 2009; 60(3):AB21-AB21.
  23. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 2016; 106(1):6-15.
  24. Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, Ibáñez L, et al. The Diagnosis of Polycystic Ovary Syndrome during Adolescence. Horm Res Paediatr 2015 ;83(6):376-89.
  25. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25(2):544-51.
  26. Akbarzadeh M, Naderi T, Dabbagh Manesh MH, Tabatabaee HR. The frequency of various phenotypes of polycystic ovarian syndrome in adolescents, based on rotterdam criteria. Int J School Health 2015; 2(3):1-5.
  27. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reproductive Biology and Endocrinology 2011; 9(1):1-7.
  28. Rashidi H, Ramezani Tehrani F, Bahri Khomami M, Tohidi M, Azizi F. To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran. Eur J Obstet Gynecol Reprod Biol 2014; 174:100-5.
  29. Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod 2014; 29(4):791-801.
  30. Joshi B, Mukherjee S, Patil A, Purandare A, Chauhan S, Vaidya R. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. Indian J Endocrinol Metab 2014; 18(3):317-24.
  31. Hashemipour M, Faghihimani S, Zolfaghary B, Hovsepian S, Ahmadi F, Haghighi S. Prevalence of polycystic ovary syndrome in girls aged 14-18 years in Isfahan, Iran. Horm Res 2004; 62(6):278-82.
  32. Esmaeilzadeh S, Delavar MA, Amiri M, Khafri S, Pasha NG. Polycystic ovary syndrome in Iranian adolescents. Int J Adolesc Med Health 2014; 26(4):559-65.
  33. Desai NA, Tiwari RY, Patel SS. Prevalence of polycystic ovary syndrome and its associated risk factors among adolescent and young girls in ahmedabad region. Indian Journal of Pharmacy Practice 2018; 11(3):119.
  34. Saei Ghare Naz M, Tehrani FR, Majd HA, Ahmadi F, Ozgoli G, Fakari FR, et al. The prevalence of polycystic ovary syndrome in adolescents: A systematic review and meta-analysis. Int J Reprod Biomed 2019; 17(8):533-542.
  35. Salehpour S, Esmaeilnia Shirvani H, Entezari A. Evaluation of the prevalence of polycystic ovarian syndrome among adolescent (15-18 Years Old) girls in Tehran during 2005-2006. International Journal of Fertility and Sterility 2010; 4(3):122-7.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 24, Issue 2
April 2021
Pages 14-22

Files

Share

How to cite

Statistics